BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 20156115)

  • 21. Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.
    Dusetzina SB; Alexander GC; Freedman RA; Huskamp HA; Keating NL
    Breast Cancer Res Treat; 2013 Jan; 137(1):285-96. PubMed ID: 23149465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.
    Cronin-Fenton DP; Lash TL
    Expert Rev Clin Pharmacol; 2011 May; 4(3):363-77. PubMed ID: 21709817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
    Binkhorst L; Mathijssen RH; van Herk-Sukel MP; Bannink M; Jager A; Wiemer EA; van Gelder T
    Breast Cancer Res Treat; 2013 Jun; 139(3):923-9. PubMed ID: 23760858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
    Hjorth CF; Nielsen AS; Sørensen HT; Lash TL; Damkier P; Hamilton-Dutoit S; Cronin-Fenton D
    Acta Oncol; 2019 Feb; 58(2):168-174. PubMed ID: 30458661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
    Zembutsu H; Sasa M; Kiyotani K; Mushiroda T; Nakamura Y
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):185-93. PubMed ID: 21342038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
    Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
    Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
    Desmarais JE; Looper KJ
    J Clin Psychiatry; 2009 Dec; 70(12):1688-97. PubMed ID: 20141708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.
    Hussaarts KGAM; Berger FA; Binkhorst L; Oomen-de Hoop E; van Leeuwen RWF; van Alphen RJ; Mathijssen-van Stein D; de Groot NMS; Mathijssen RHJ; van Gelder T
    Pharm Res; 2019 Dec; 37(1):7. PubMed ID: 31845095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
    Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
    Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen-SSRIs interaction: clinical manifestations of inhibition and lack of inhibition of CYP2D6.
    Appiani F; Carroll BT; Muñoz C; Trecco J
    Ann Clin Psychiatry; 2011 May; 23(2):152-3. PubMed ID: 21547277
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    Pharoah PD; Abraham J; Caldas C
    J Natl Cancer Inst; 2012 Aug; 104(16):1263-4; author reply 1266-8. PubMed ID: 22851268
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Ponzone R; Biglia N; Sismondi P
    J Natl Cancer Inst; 2004 Jun; 96(11):883-4; author reply 884-5. PubMed ID: 15173274
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
    Kaufmann M; Rody A
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):487-94. PubMed ID: 15915367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients.
    Ahern TP; Collin LJ; Baurley JW; Kjærsgaard A; Nash R; Maliniak ML; Damkier P; Zwick ME; Isett RB; Christiansen PM; Ejlertsen B; Lauridsen KL; Christensen KB; Silliman RA; Sørensen HT; Tramm T; Hamilton-Dutoit S; Lash TL; Cronin-Fenton D
    Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):582-590. PubMed ID: 31932415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
    Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
    J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
    Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy.
    Mayer SE; Weiss NS; Chubak J; Doody DR; Carlson CS; Makar KW; Wurscher MA; Malone KE
    Cancer Causes Control; 2019 Jan; 30(1):103-112. PubMed ID: 30542984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition.
    Lehmann D; Nelsen J; Ramanath V; Newman N; Duggan D; Smith A
    J Clin Pharmacol; 2004 Aug; 44(8):861-5. PubMed ID: 15286089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.